药师帮(09885)发布公告，执行董事陈飞先生已于2025年11月12日在公开市场购入合共10万股股份。陈 先生自2025年4月以来已累计增持130万股股份，并计划进一步增持。董事会认为，陈先生增持股份显示 其对公司前景及增长潜力充满信心，亦展示其对公司的长期承诺。 ...

智通财经APP讯，药师帮(09885)发布公告，于2025年11月12日，公司根据2025年股份回购授权回购股 份。合共10万股股份已于市场回购，总回购金额约为81.87万港元(不包括佣金及其他开支)，平均回购价 为每股8.1865港元。回购股份将适时注销。 ...

智通财经APP讯，药师帮(09885)发布公告，执行董事陈飞先生已于2025年11月12日在公开市场购入合共 10万股股份。陈先生自2025年4月以来已累计增持130万股股份，并计划进一步增持。董事会认为，陈先 生增持股份显示其对公司前景及增长潜力充满信心，亦展示其对公司的长期承诺。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 自願性公告 股份回購 董 事 會 進 一 步 宣 佈，於2025年11月12日，本 公 司 根 據2025年股份回購授權回購 股 份。合 共100,000股 股 份 已 於 市 場 回 購，總 回 購 金 額 約 為818,650港 元（不 包 括 佣 金 及 其 他 開 支），平 均 回 購 價 為 每 股8.1865港 元。回 購 股 份 將 適 時 註 銷。 – 1 – 董 事 會 認 為，本 公 司 目 前 的 股 價 低 於 其 真 正 價 值，未 能 充 分 反 映 其 業 務 前 景。 董 事 會 認 為，股 份 回 購 計 劃 顯 示 董 事 及 本 公 司 高 級 管 理 層 對 本 公 司 的 長 期 ...

Core Viewpoint - The recent strong performance of the pharmaceutical retail and distribution sectors in A-shares and Hong Kong stocks is driven by an unusually high level of autumn flu activity, leading to heightened market expectations for the earnings resilience of pharmaceutical companies [1][2]. Group 1: Market Performance - The flu cases in northern provinces reached 5.1% of total emergency visits as of November 2, the highest since February 2025, while southern provinces saw flu cases rise to 4.6%, the highest since June 2025 [1]. - The significant increase in flu activity compared to the previous year has led to a surge in demand expectations for cold, fever, and antiviral medications [1]. - The pharmaceutical commercial sector, acting as a key link between drug production and end consumption, is expected to experience a short-term boost in business volume, including retail pharmacy sales and distribution volumes [1]. Group 2: Investment Trends - Market funds are proactively positioning themselves in the pharmaceutical commercial sector, which is currently valued relatively low, based on the anticipated earnings improvements due to the flu outbreak [1]. - The overall valuation recovery of the sector is driven by improved fundamental expectations, with market participants keenly capturing this change [1]. - Within this rally, companies with stronger supply chain capabilities, broader network coverage, or unique business models are favored by investors, with leading stocks like Dazhenglin and Yifeng Pharmacy showing active performance [2]. Group 3: Long-term Considerations - The sustainability of the sector's performance is closely tied to corporate earnings, and investors are advised to focus on companies that enhance their core competitiveness and possess resilient business models amid industry changes [2]. - While short-term event-driven opportunities are important, attention should also be given to the long-term value of these companies [2].

Group 1: Health Education and Management - The China International Import Expo (CIIE) serves as a platform for disseminating health science and advanced treatment techniques, focusing on obesity management and chronic disease care [1][2] - A new encyclopedia on weight management was launched, emphasizing the need for scientific approaches to obesity under medical guidance, with contributions from 180 experts [1] - The collaboration between WeDoctor and Abbott aims to establish a comprehensive digital management system for diabetes, shifting from reactive treatment to proactive health management [2] Group 2: Cancer Treatment Innovations - Lung cancer precision treatment is a key focus, with discussions on the importance of exploring combination therapies for rare target mutations [2][3] - Bayer is committed to enhancing drug accessibility and developing innovative treatments in collaboration with clinical experts [3] Group 3: Chronic Kidney Disease and Cardiovascular Management - The concept of Cardiovascular-Kidney-Metabolic (CKM) syndrome highlights the interconnectedness of diseases like obesity, diabetes, and chronic kidney disease, necessitating a holistic management approach [3][4] - Experts advocate for early detection and intervention in CKM-related diseases, emphasizing the role of endocrinology in managing these conditions [4] - The China Population Welfare Foundation is working to integrate resources for CKM management, promoting a collaborative model that involves medical, public welfare, and social participation [4] Group 4: Technological Advancements in Medical Procedures - The trend towards intelligent and minimally invasive spinal surgery is being supported by new technologies introduced at the CIIE, including navigation-assisted endoscopic techniques [4]

Core Viewpoint - The company, Yaoshi Bang, has been actively repurchasing its shares, indicating a strategy to support its stock price amidst recent declines [2][3]. Share Buyback Summary - On November 7, the company repurchased 400,000 shares at a price range of HKD 7.970 to HKD 8.090, totaling HKD 3.2188 million [2]. - The stock closed at HKD 8.040 on the same day, reflecting a decrease of 0.25%, with a total trading volume of HKD 88.1949 million [2]. - Since November 6, the company has conducted buybacks for two consecutive days, accumulating a total of 800,000 shares repurchased for HKD 6.4541 million, during which the stock price fell by 5.63% [2]. Year-to-Date Buyback Activity - Year-to-date, the company has executed 25 buybacks, totaling 6.935 million shares and an aggregate amount of HKD 56.036 million [3]. - The detailed buyback activity includes various dates, share quantities, and price ranges, showcasing a consistent effort to stabilize the stock price [3][4].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期： 2025年11月7日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09885 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件 ...

Core Viewpoint - The company, Yaoshi Bang (09885), announced a share buyback on November 7, 2025, under its 2025 share repurchase authorization [1] Summary by Relevant Sections - **Share Buyback Details** - A total of 400,000 shares were repurchased from the market [1] - The total amount spent on the buyback was approximately HKD 3.219 million, excluding commissions and other expenses [1] - The average repurchase price was HKD 8.0469 per share [1] - The repurchased shares will be canceled in due course [1]

Group 1 - The company, Yaoshibang (09885), announced a share buyback on November 7, 2025, under the 2025 share buyback authorization [1] - A total of 400,000 shares were repurchased from the market, with a total expenditure of approximately HKD 3.219 million, excluding commissions and other expenses [1] - The average repurchase price was HKD 8.0469 per share, and the repurchased shares will be canceled in due course [1]